80 related articles for article (PubMed ID: 34050139)
1. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity.
Fernández-Tussy P; Rodríguez-Agudo R; Fernández-Ramos D; Barbier-Torres L; Zubiete-Franco I; Davalillo SL; Herraez E; Goikoetxea-Usandizaga N; Lachiondo-Ortega S; Simón J; Lopitz-Otsoa F; Juan VG; McCain MV; Perugorria MJ; Mabe J; Navasa N; Rodrigues CMP; Fabregat I; Boix L; Sapena V; Anguita J; Lu SC; Mato JM; Banales JM; Villa E; Reeves HL; Bruix J; Reig M; Marin JJG; Delgado TC; Martínez-Chantar ML
Cell Death Dis; 2021 May; 12(6):555. PubMed ID: 34050139
[TBL] [Abstract][Full Text] [Related]
2. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis.
Wu H; Wang T; Liu Y; Li X; Xu S; Wu C; Zou H; Cao M; Jin G; Lang J; Wang B; Liu B; Luo X; Xu C
J Exp Clin Cancer Res; 2020 Dec; 39(1):274. PubMed ID: 33280610
[TBL] [Abstract][Full Text] [Related]
3. FAM225A promotes sorafenib resistance in hepatocarcinoma cells through modulating miR-130a-5p-CCNG1 interaction network.
Liu YT; Liu GQ; Huang JM
Biosci Rep; 2020 Nov; 40(12):. PubMed ID: 33245102
[TBL] [Abstract][Full Text] [Related]
4. CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death.
Ding B; Bao C; Jin L; Xu L; Fan W; Lou W
Front Oncol; 2021; 11():681683. PubMed ID: 34249726
[TBL] [Abstract][Full Text] [Related]
5. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis.
Serrano-Maciá M; Simón J; González-Rellan MJ; Azkargorta M; Goikoetxea-Usandizaga N; Lopitz-Otsoa F; De Urturi DS; Rodríguez-Agudo R; Lachiondo-Ortega S; Mercado-Gomez M; Gutiérrez de Juan V; Bizkarguenaga M; Fernández-Ramos D; Buque X; Baselli GA; Valenti LVC; Iruzubieta P; Crespo J; Villa E; Banales JM; Avila MA; Marin JJG; Aspichueta P; Sutherland J; Barrio R; Mayor U; Elortza F; Xirodimas DP; Nogueiras R; Delgado TC; Martínez-Chantar ML
Mol Metab; 2021 Nov; 53():101275. PubMed ID: 34153521
[TBL] [Abstract][Full Text] [Related]
6. PLEKHO2 inhibits TNFα-induced cell death by suppressing RIPK1 activation.
Zhou C; Zhang X; Yang C; He Y; Zhang L
Cell Death Dis; 2021 Jul; 12(8):714. PubMed ID: 34272357
[TBL] [Abstract][Full Text] [Related]
7. MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma.
Liu Y; Zhang Y; Xiao B; Tang N; Hu J; Liang S; Pang Y; Xu H; Ao J; Yang J; Liang X; Wei L; Wang Y; Luo X
Cell Death Dis; 2021 Jun; 12(6):618. PubMed ID: 34131101
[TBL] [Abstract][Full Text] [Related]
8. Deregulated 14-3-3ζ and methionine adenosyltransferase α1 interplay promotes liver cancer tumorigenesis in mice and humans.
Lu L; Zhang J; Fan W; Li Y; Wang J; Li TWH; Barbier-Torres L; Mato JM; Liu T; Seki E; Matsuda M; Tomasi ML; Bhowmick NA; Yang H; Lu SC
Oncogene; 2021 Sep; 40(39):5866-5879. PubMed ID: 34349244
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals.
Goikoetxea-Usandizaga N; Serrano-Maciá M; Delgado TC; Simón J; Fernández Ramos D; Barriales D; Cornide ME; Jiménez M; Pérez-Redondo M; Lachiondo-Ortega S; Rodríguez-Agudo R; Bizkarguenaga M; Zalamea JD; Pasco ST; Caballero-Díaz D; Alfano B; Bravo M; González-Recio I; Mercado-Gómez M; Gil-Pitarch C; Mabe J; Gracia-Sancho J; Abecia L; Lorenzo Ó; Martín-Sanz P; Abrescia NGA; Sabio G; Rincón M; Anguita J; Miñambres E; Martín C; Berenguer M; Fabregat I; Casado M; Peralta C; Varela-Rey M; Martínez-Chantar ML
Hepatology; 2022 Mar; 75(3):550-566. PubMed ID: 34510498
[TBL] [Abstract][Full Text] [Related]
10. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L.
Akamatsu H; Murakami H; Harada H; Shimizu J; Hayashi H; Daga H; Hasegawa Y; Kim YH; Kato T; Tokunaga S; Nishimura Y; Yamamoto N; Nakagawa K
J Thorac Oncol; 2021 Oct; 16(10):1745-1752. PubMed ID: 34116229
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
Son Y; Shin NR; Kim SH; Park SC; Lee HJ
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373
[TBL] [Abstract][Full Text] [Related]
13. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance.
Marin JJG; Sanchon-Sanchez P; Cives-Losada C; Del Carmen S; González-Santiago JM; Monte MJ; Macias RIR
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34068398
[TBL] [Abstract][Full Text] [Related]
14. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
[TBL] [Abstract][Full Text] [Related]
15. Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells.
Rodrigo MAM; Michalkova H; Jimenez AMJ; Petrlak F; Do T; Sivak L; Haddad Y; Kubickova P; de Los Rios V; Casal JI; Serrano-Macia M; Delgado TC; Boix L; Bruix J; Martinez Chantar ML; Adam V; Heger Z
Biomark Res; 2024 Apr; 12(1):38. PubMed ID: 38594765
[TBL] [Abstract][Full Text] [Related]
16. Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response.
Vianello C; Monti E; Leoni I; Galvani G; Giovannini C; Piscaglia F; Stefanelli C; Gramantieri L; Fornari F
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398157
[TBL] [Abstract][Full Text] [Related]
17. Research progress of circulating non-coding RNA in diagnosis and treatment of hepatocellular carcinoma.
You J; Xia H; Huang Z; He R; Zhao X; Chen J; Liu S; Xu Y; Cui Y
Front Oncol; 2023; 13():1204715. PubMed ID: 37546394
[TBL] [Abstract][Full Text] [Related]
18. Little things with significant impact: miRNAs in hepatocellular carcinoma.
Li J; Bao H; Huang Z; Liang Z; Wang M; Lin N; Ni C; Xu Y
Front Oncol; 2023; 13():1191070. PubMed ID: 37274242
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy.
Kouroumalis E; Tsomidis I; Voumvouraki A
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189787
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing?
Gramantieri L; Fornari F
Oncoscience; 2022; 9():52-54. PubMed ID: 36128258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
